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Abstract
Background: Zoledronic acid is very widely used in patients with metastatic bone disease and
osteoporosis. Only one case of bilateral uveitis was recently reported related to its use.
Case presentation: We report the first case of severe unilateral anterior uveitis in a patient with
breast cancer and an intraocular lens. Following zoledronic acid infusion, the patient developed
severe and dramatic right eye pain with decreased visual acuity within 24 hours and was found to
have a fibrinous anterior uveitis of moderate severity The patient was treated with topical
prednisone and atropine eyedrops and recovered slowly over several months.
Conclusion: Internists, oncologists, endocrinologists, and ophtalmologists should be aware of
uveitis as a possible complication of zoledronic acid therapy. Patients should be instructed to report
immediately to their physicians and treatment with topical prednisone and atropine eyedrops
should be instituted immediately at the onset of symptoms. This report documents anterior uveitis
as a complication of zoledronic acid therapy. This reaction could be an idiosyncratic one but further
research may shed more light on the etiology.
Background
Bisphosphonates are very widely used the the treatment of
metastatic bone disease and osteoporosis. They are struc-
turally analogues to pyrophosphates. They inhibit
hydroxyapatite crystal development and dissolution by
affecting the ionic makeup of the hydration layer that sur-
rounds the crystals in suspension [1]. They also inhibit
osteoclasts. They are very commonly used for osteoporo-
sis and for cancer patients with metastatic bone disease.
The most commonly used bisphophonates are etidronate,
clodronate, pamidronate, alendronate and more recently
zoledronic acid. Zoledronic acid is generally very well tol-
erated. General side effects of bisphosphonates include
transient low-grade fever, fatigue, arthralgia or myalgia,
nausea, increased bone pain, fluctuations in serum ion
levels (calcium, magnesium, and phosphorus), and occa-
sional elevations in serum creatinine [2].
Severe anterior uveitis has been reported with alendronate
[3-5] and pamidronate [6-8]. One recent case report
described uveitis as a complication of zoledronic acid in a
patient with a normal eye [9]. That patient was reported to
have suffered from bilateral anterior uveitis with concur-
rent bilateral conjunctivitis after 48 hours of administra-
tion of zoledronic acid. This is the first case of acute
unilateral anterior uveitis in a patient with an intraocular
lens.
Published: 06 December 2005
BMC Cancer 2005, 5:156 doi:10.1186/1471-2407-5-156
Received: 26 June 2005
Accepted: 06 December 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/156
© 2005 El Saghir et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
BMC Cancer 2005, 5:156 http://www.biomedcentral.com/1471-2407/5/156Case presentation
A 60-year-old woman was diagnosed to have a left breast
cancer stage T2 N1 M0 hormone receptor-positive in 1997.
She was treated with modified radical mastectomy, adju-
vant chemotherapy with cyclophosphamide, adriamycin
and 5-fluorouracil, followed by adjuvant hormonal ther-
apy. She completed five years of adjuvant tamoxifen in
2003 and and was started on letrozole adjuvant therapy in
January 2004 [10].
The patient had an ocular history significant for bilateral
dacryocystitis, cataracts and open angle glaucoma, left
dacryocystectomy (DCR) in 1997, right DCR in 2000 and
2003, as well as a right eye phacoemulsification with
implantation of a hydrophilic acrylic intraocular lens in
2003 with a postoperative uncorrected visual acuity of 20/
25. The patient was maintained on antiglaucoma treat-
ment in the form of topical beta blocker eyedrops for both
eyes, combined with prostaglandin eyedrops for her left
eye.
The patient was scheduled to have zoledronic acid 4 mg
once every six months for osteoporosis. In August 2004,
the patient was given intravenous hydration with normal
saline, premedicated with paracetamol, and had an intra-
venous infusion of zoledronic acid 4 mg in 100 cc normal
saline given over 30 minutes. The patient did well
throughout the infusion; however, she felt chilly and
feverish overnight. The next day, she presented to the
Emergency Department complaining of severe right eye
pain and decreased vision. Examination revealed uncor-
rected visual acuity of 20/100 in the right eye and 20/60
in the left eye. The intraocular pressure was 14 mmHg in
both eyes. Slit lamp examination revealed marked ciliary
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cells in the anterior chamber. An inflammatory fibrinous
pupillary membrane was also present (Fig 1). Fundus
examination was normal. A diagnosis of right anterior
uveitis was made. The patient was placed on topical pred-
nisone every 6 hours, and atropine eyedrops every 12
hours. She responded well to the treatment which was
gradually tapered off over a period of 6 weeks without
recurrence of uveitis. Following treatment, visual acuity in
the right eye improved to 20/30, and slit lamp examina-
tion revealed slight opacification of the posterior capsule
(Fig 2), and residual pigmented deposits on the surface of
the intraocular lens (Fig 3). These inflammatory changes
and deposits on the posterior lens surface disappeared on
their own over a period of 3 months, but residual poste-
rior capsular opacification (PCO) is still present. This
PCO has no effect on the patient's visual acuity at present
and doesn't require any intervention.
Unlike in metastatic bone diseases where bisphosphonate
therapy is administered on a monthly basis, our plan was
to give the patient zoledronic acid every six months [11].
The patient refused to have any further bisphosphonate
therapy
Conclusion
This is the first report of unilateral anterior uveitis occur-
ing within 24 hours of zoledronic acid in a patient with an
implanted intraocular lens. The clinical symptoms were
severe and dramatic but the ophtalmologic examination
showed a fibrinous anterior uveitis of moderate severity.
The patient gradually responded well to treatment and
recovered after three months with no major sequalae. The
inflammatory deposits on the posterior lens surface disap-
peared over a period of 3 months, except for residual PCO
which is a common occurrence after cataract surgery and
intraocular inflammation [12].
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for metastatic bone disease and osteoporosis because of
its relative higher potency and short infusion time. Every
internist, oncologist, endocrinologist, and ophtalmolo-
gist should be aware of uveitis as a possible complication
of zoledronic acid. Careful review of systems should
include ophtalmologic history. Patients should be
instructed to immediately report to their physicians any
eye complaints. Treatment with topical prednisone and
atropine eyedrops should be instituted immediately at the
onset of symptoms. Patients should be instructed to con-
sult their ophthalmologist for any ocular complaints.
Close follow-up of these patients should also be made.
This report documents anterior uveitis as a complication
of zoledronic acid therapy. This side effect could be an idi-
osyncratic reaction but research into etiology may shed
more light on mechanisms of action of bisphosphonates
and interaction with lenses, if any.
Repeating the administration of zoledronic acid in these
patients with prophylactic topical steroids and atropine
remains an unresolved issue. In one case report of uveitis
associated with clodronate, the patient developed the
same ocular symptoms when rechallenged with the same
drug [13].
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